Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition with kidney protection effect

A composition and drug technology, applied in the field of pharmacy, can solve problems affecting the quality of life of patients, and achieve the effects of protecting the kidneys, lowering the dosage of drugs, and reducing the level of proteinuria

Active Publication Date: 2021-03-05
SHENZHEN AUSA PHARM CO LTD +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The cost of medical services for CKD patients is 1.8 times that of people without chronic kidney disease, and the average cost of medical services for dialysis patients is 10.3 times that of people without chronic kidney disease, which brings a huge economic burden to patients and seriously affects their quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition with kidney protection effect
  • Pharmaceutical composition with kidney protection effect
  • Pharmaceutical composition with kidney protection effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-6

[0027] Embodiment 1-6. Atrasentan + enalapril + folic acid tablets (1000 pieces)

[0028]

[0029] Preparation Process:

[0030] Mix atrasentan, enalapril and folic acid, add carboxymethyl starch sodium and sodium lauryl sulfate, then add microcrystalline cellulose and pregelatinized starch and mix evenly, and use an appropriate amount of 10% povidone The ethanol solution is made into a soft material, granulated, dried, and granulated, and the granules with a water content of about 3% are evenly mixed with an appropriate amount of magnesium stearate, and compressed into 1,000 tablets.

Embodiment 7-12

[0031] Example 7-12. Atrasentan + enalapril + folic acid capsules (1000 capsules)

[0032]

[0033]Preparation process: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Mix atrasentan, enalapril, and folic acid evenly, add lactose crystals, polyvinylpyrrolidone, microcrystalline cellulose, and sodium carboxymethyl starch, mix evenly, make a soft material with micro-powder silica gel, and granulate with a 20-mesh sieve , dry at 60°C for about 2 hours, granulate with a 20-mesh sieve, control the water content of the granules to 2-3%, mix the dried granules with an appropriate amount of 1% magnesium stearate, test the semi-finished products, measure the content, and pack Empty capsules, that is, 1000 capsules. Protect from light during preparation. After the finished product passes the inspection, it is packed in aluminum-plastic blister and stored away from light.

Embodiment 13

[0034] Example 13: The renoprotective effect of atrasentan + enalapril folic acid composition on rats with chronic kidney disease.

[0035] (1) Modeling:

[0036] Adult Wistar rats, male, weighing 200-220g, were fed with common feed and quarantined for 7 days. Animals whose body weight deviation exceeded 10% were excluded, and 10 rats were randomly selected as the normal control group, and fed with normal feed until the end of the experiment. Animals in the modeling group were fasted for 12 hours before modeling, and received a single tail vein injection of doxorubicin (7.9 mg / kg), and resumed normal diet and drinking water 2 hours after modeling. After 4 weeks, the 24-h urinary protein levels of all animals were detected, and model animals with 24-h urinary protein ≥ 20 mg were selected to enter the follow-up experiment.

[0037] (2) Grouping and administration:

[0038] There were 10 rats in the normal control group, and the successfully modeled animals were randomly divid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition with a kidney protection effect. The pharmaceutical composition consists of an endothelin inhibitor, enalapril, folic acid substances and a pharmaceutically acceptable carrier, wherein the endothelin inhibitor comprises atrasentan. The invention provides application of the pharmaceutical composition to preparation of medicines for preventing, treating or delaying chronic kidney diseases and diabetic nephropathy. Through the implementation of the application, the pharmaceutical composition is provided for patients, the curative effect can beimproved, the treatment compliance is increased, and the medical cost is reduced.

Description

technical field [0001] The invention relates to a pharmaceutical composition combined with an endothelin inhibitor, enalapril and folic acid substances and its application, belonging to the field of pharmacy. Background technique [0002] Chronic kidney disease (CKD) is a chronic kidney structure and dysfunction caused by various reasons. It is estimated that about 500 million people in the world have different degrees of kidney disease. Therefore, CKD has become a global health problem. . The cost of medical services for CKD patients is 1.8 times that of people without chronic kidney disease, and the average cost of medical services for dialysis patients is 10.3 times that of people without chronic kidney disease. This brings a huge economic burden to patients and seriously affects their quality of life. In addition, the morbidity and mortality of cardiovascular diseases in CKD patients are significantly higher than those in the general population, and they appear early an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4025A61K38/05A61K31/40A61K31/519A61P13/12A61P3/10A61P9/12
CPCA61K31/4025A61K38/05A61K31/40A61K31/519A61P13/12A61P3/10A61P9/12A61K2300/00
Inventor 段洪伟白洁张磊陈光亮徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com